Skip to main content
Fig. 3 | Clinical Sarcoma Research

Fig. 3

From: Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis

Fig. 3

One way sensitivity analysis evaluating incremental cost effectiveness ratios (ICERs) of UAPR compared with CIUP for a range of annual recurrence probabilities post abdominoperineal resection. Below a recurrence probability of 12%, UAPR dominates CIUP–it costs less and is more effective, thus generating no meaningful ICER. The range of recurrence probabilities considered thus begins with 15%

Back to article page